Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Recruiting now NCT06218433
Run by Tampere University Hospital · for 50 to 75 · All sexes · accepts healthy volunteers
What this study is about
Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and endometrial cancers in individuals with LS. Up to one in four LS individuals will develop urothelial cancer during their lifetime, with the risk varying based on the defective MMR gene. In this clinical trial, we will employ urine tumor DNA (utDNA) to identify asymptomatic urothelial cancers in Lynch syndrome patients, and to investigate the potential benefits of urine tumor DNA based screening in this high-risk population.
Who can join (things the study team will check)
✅ You may be able to join if…
- Willing and able to provide informed consent
- Diagnosis of Lynch syndrome
- Age 50 - 75 years at study recruitment
🚫 You may not be able to join if…
- Concurrent urothelial carcinoma
Where this trial is running
- Vancouver Prostate Centre, Vancouver, Canada
- Tampere University Hospital and Tampere University, Tampere, Finland
Who to contact
Jussi Nikkola, MD, PhD · 03311611 · jussi.nikkola@fimnet.fi
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06218433.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.